BACKGROUND: Preterm neonates are usually not part of a traditional drug development programme, however they are frequently administered medicines. Developing modelling and simulation tools, such as physiologically based pharmacokinetic (PBPK) models that incorporate developmental physiology and maturation of drug metabolism, can be used to predict drug exposure in this group of patients, and may help to optimize drug dose adjustment. OBJECTIVE: The aim of this study was to assess and verify the predictability of a preterm PBPK model using compounds that undergo diverse renal and/or hepatic clearance based on the knowledge of their disposition in adults. METHODS: A PBPK model was developed in the Simcyp Simulator V17 to predict the pharmacokinetics (PK) of drugs in preterm neonates. Drug parameters for alfentanil, midazolam, caffeine, ibuprofen, gentamicin and vancomycin were collated from the literature. Predicted PK parameters and profiles were compared against the observed data. RESULTS: The preterm PBPK model predicted the PK changes of the six compounds using ontogeny functions for cytochrome P450 (CYP) 1A2, CYP2C9 and CYP3A4 after oral and intravenous administrations. For gentamicin and vancomycin, the maturation of renal function was able to predict the exposure of these two compounds after intravenous administration. All PK parameter predictions were within a twofold error criteria. CONCLUSION: While the developed preterm model for the prediction of PK behaviour in preterm patients is not intended to replace clinical studies, it can potentially help with deciding on first-time dosing in this population and study design in the absence of clinical data.
BACKGROUND: Preterm neonates are usually not part of a traditional drug development programme, however they are frequently administered medicines. Developing modelling and simulation tools, such as physiologically based pharmacokinetic (PBPK) models that incorporate developmental physiology and maturation of drug metabolism, can be used to predict drug exposure in this group of patients, and may help to optimize drug dose adjustment. OBJECTIVE: The aim of this study was to assess and verify the predictability of a preterm PBPK model using compounds that undergo diverse renal and/or hepatic clearance based on the knowledge of their disposition in adults. METHODS: A PBPK model was developed in the Simcyp Simulator V17 to predict the pharmacokinetics (PK) of drugs in preterm neonates. Drug parameters for alfentanil, midazolam, caffeine, ibuprofen, gentamicin and vancomycin were collated from the literature. Predicted PK parameters and profiles were compared against the observed data. RESULTS: The preterm PBPK model predicted the PK changes of the six compounds using ontogeny functions for cytochrome P450 (CYP) 1A2, CYP2C9 and CYP3A4 after oral and intravenous administrations. For gentamicin and vancomycin, the maturation of renal function was able to predict the exposure of these two compounds after intravenous administration. All PK parameter predictions were within a twofold error criteria. CONCLUSION: While the developed preterm model for the prediction of PK behaviour in preterm patients is not intended to replace clinical studies, it can potentially help with deciding on first-time dosing in this population and study design in the absence of clinical data.
Authors: J V Aranda; A Varvarigou; K Beharry; R Bansal; C Bardin; H Modanlou; A Papageorgiou; S Chemtob Journal: Acta Paediatr Date: 1997-03 Impact factor: 2.299
Authors: E D Kharasch; A Walker; N Isoherranen; C Hoffer; P Sheffels; K Thummel; D Whittington; D Ensign Journal: Clin Pharmacol Ther Date: 2007-06-06 Impact factor: 6.875
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2021-02-02 Impact factor: 5.577
Authors: Laurens F M Verscheijden; Carlijn H C Litjens; Jan B Koenderink; Ron H J Mathijssen; Marcel M Verbeek; Saskia N de Wildt; Frans G M Russel Journal: PLoS Comput Biol Date: 2021-03-04 Impact factor: 4.475
Authors: Hinojal Zazo; Eduardo Lagarejos; Manuel Prado-Velasco; Sergio Sánchez-Herrero; Jenifer Serna; Almudena Rueda-Ferreiro; Ana Martín-Suárez; M Victoria Calvo; Jonás Samuel Pérez-Blanco; José M Lanao Journal: Front Pharmacol Date: 2022-09-28 Impact factor: 5.988
Authors: Jolien J M Freriksen; Joyce E M van der Heijden; Marika A de Hoop-Sommen; Rick Greupink; Saskia N de Wildt Journal: Paediatr Drugs Date: 2022-10-06 Impact factor: 3.930